ライフサイエンスコーパス: consent to

1 mber of donor management goals achieved from consent to 12-18 hrs later (odds ratio=1.13 per addition

2 with elevated cancer risk and dense breasts consented to 3 annual independent screens with mammograp

3 Patients prospectively consented to 5 years of follow-up.

4 Patients prospectively consented to 5 years of follow-up.

5 majority (83%) were willing to grant advance consent to a blood draw study, and nearly half (48%) to

6 the responsibility for advising a patient to consent to a cardiac operation using honestly presented

7 ity to appoint a research proxy, capacity to consent to a drug RCT, and capacity to consent to a neur

8 Each patient provided written consent to a human subject protocol approved by an insti

9 ic symptoms, and ability to provide informed consent to a hypothetical drug trial.

10 ty to consent to a drug RCT, and capacity to consent to a neurosurgical RCT.

11 sumed advanced ovarian cancer, were asked to consent to a postoperative CT scan if cytoreduction to <

12 Participants provided written informed consent to a protocol that was approved by a local resea

13 Lack of consent to a request for donation was the primary cause

14 utinely to evaluate individuals' capacity to consent to a research protocol.

15 Subjects consented to a "study of diseases of public health impor

16 ic patients undergoing colonoscopy screening consented to a CTC examination.

17 Of these, 125 consented to a follow-up transesophageal echocardiogram

18 between February 2003 and September 2005 who consented to a survey and medical record review (61% res

19 lant candidates (KTCs) must provide informed consent to accept kidneys from increased risk donors (IR

20 oard of the university, and written informed consent to acquire and analyze MR spectroscopic imaging

21 , after which >80% of surviving participants consented to additional active follow-up through Septemb

22 domized participants and censoring those not consenting to additional follow-up on March 31, 2005, es

23 The participants are also being consented to allow the contact of family members for add

24 the patient and the referring physician have consented to allow their data to be used for research.

25 sified) or grade I-IV COPD provided informed consent to an ethics board-approved HIPAA-compliant prot

26 rse events (AEs), participants were asked to consent to an extended follow-up phase in order to asses

27 tu hybridization of colon tissue-the patient consented to an analytic treatment interruption (ATI) wi

28 red because the donors had registered in and consented to an anatomic gift program prior to their dea

29 3 for up to 60 months in 6 of 8 patients who consented to an end-of-study biopsy.

30 A total of 3492 15- to 22-year-old MSM who consented to an interview and HIV testing.

31 o attended the final blinded study visit and consented to anal specimen collection were included in t

32 Seventy-two patients consented to analyses of tumor epidermal growth factor r

33 surviving children, 3324 were revisited and consented to anthropometric measurements.

34 lth-record abstraction were done for all who consented to ascertain potential interpersonal connectio

35 inical trial, 268 active-duty servicemembers consented to assessment at an army medical center from M

36 463 were randomly selected, and 267 (57.7%) consented to assessment of their HPA axis function.

37 cal opinions regarding patient competence to consent to assisted suicide.

38 at should be used to determine competence to consent to assisted suicide.

39 articipants and a subset of ACT participants consent to autopsy.

40 nts with biopsy-proven PCa provided informed consent to be included in this institutional human ethic

41 linicians and patients provided full written consent to be interviewed and have appointments audio-re

42 Practices that did not consent to be randomly assigned comprised a practice-as-

43 d their donor card, one might consider their consent to be truly informed and valid.

44 w of medical records and determined informed consent to be unnecessary.

45 igned to treatment as usual) were traced and consented to be assessed between July, 2013, and Septemb

46 Women in the pregnancy cohort who consented to be contacted for participation in future st

47 tween January 1, 1970, and November 1, 2014, consented to be included in the Mayo Clinic amyloidosis

48 2100 participants in the CHHiP trial consented to be included in the QoL substudy: 696 assign

49 Of the 116 who consented to be included in the study, 112 (97%, 95% CI

50 , 134 accessed their results online, and 105 consented to be included.

51 81 were acceptable for CABG and PCI, and 454 consented to be randomized.

52 n, did not require additional treatment, and consented to be randomly assigned to double-blind mainte

53 ified from an in-house database, 53 patients consented to be screened.

54 vivors, of whom 47 could be contacted and 22 consented to be studied.

55 setting, a patient with open-angle glaucoma consented to be the recipient of the WIT in one eye in a

56 was conducted with 465 participating mothers consenting to be followed up at 3 years after interventi

57 y the 12 month follow-up and had given their consent to being re-contacted.

58 ne (18)F-FDG PET/CT for various malignancies consented to being scanned for CL.

59 r analyses were done on all treated patients consenting to biomarker analyses and providing a measura

60 RCT) scanning in an ongoing cohort study; 72 consented to bronchoscopy with bronchoalveolar lavage (B

61 tructured assessments of adults' capacity to consent to clinical treatment or research protocols.

62 Meanwhile, parents and patients who consent to clitoral surgery should be fully informed of

63 riod were screened for eligibility; informed consent to collect baseline and outcome data was sought

64 enrolled were identified retrospectively and consented to compare survival in patients treated by sta

65 63 women with stillbirth enrolled, 500 women consented to complete postmortem examinations of 512 neo

66 that time had required levodopa and who had consented to continuing the deprenyl treatment (D subjec

67 Before consenting to copulate, a female fruit fly gauges both h

68 We also received written consent to copy their medical records for the most recen

69 Patients should be offered the option of consenting to CPR for "higher-success" situations, inclu

70 ng consent forms, and literature on informed consent to create suggested language for informed consen

71 al invasive bacterial disease were asked for consent to culture their child's blood/body fluid.

72 Subjects gave consent to deposit phenotypic data and blood samples int

73 ractice for a nonprocedural office visit who consented to direct observation and 273 patients whose p

74 L1TC to increase the number of families who consent to donate and to provide system management for t

75 se, permit, or identification card increased consent to donate organs among white and black participa

76 LIMITATION: How the observed increases in consent to donate organs might translate into a greater

77 mily members who had recently been asked for consent to donate the organs of a deceased family member

78 More participants who viewed the video consented to donate organs than control participants (84

79 ) whether, when, and how to ask families for consent to donation or (b) characteristics of families o

80 ectives of requesting and encouraging family consent to donation, (2) the effect of the donation deci

81 erable barriers exist for Hispanic Americans consent to donation, resulting in significantly lower do

82 ne follow-up, and administration of informed consent to eligible women.

83 nd additional risk factors provided informed consent to enroll in an institutional review board-appro

84 he importance of ensuring that participants' consent to enroll in clinical trials is not the result o

85 oval for consenting processes or a waiver of consent to enroll participants, link data, and perform a

86 onsenting processes or to obtain a waiver of consent to enroll participants, link data, and perform a

87 s independently indicated whether they would consent to enroll the patient in the same scenarios.

88 entified with a functioning graft at 2 years consented to enroll in an observational, nonintervention

89 pants were 1770 (80%) WARSS participants who consented to enroll in the APASS, with usable baseline b

90 Seventy-one HT recipients consented to enroll.

91 more, had no contraindications to iuMRI, and consented to enter the study.

92 To determine how often study participants' consent to examine DNA is denied and the factors associa

93 The median time from informed consent to expression analysis was 11 days.

94 gender, and symptom under investigation with consent to follow-up and consent to review of medical re

95 Consent to follow-up was also higher among responders wh

96 Consent to follow-up was approximately 75-95% among surv

97 or unavailability of the device (n = 4) but consented to follow-up and constitute a contemporaneous

98 luded in the original trial were located and consented to follow-up assessment.

99 tudy that enrolled 153 patients, of whom 111 consented to follow-up for 36 months.

100 nt for nonvirologic reasons and four did not consent to genetic testing.

101 drial haplogroups in A5005s participants who consented to genetic analyses.

102 nd phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samp

103 seen in the ED with shortness of breath were consented to have BNP levels drawn on arrival.

104 e-designated comprehensive cancer center and consented to have information stored in a prospective da

105 6 participants who received active treatment consented to have their clinical and radiologic data inc

106 le patients responded to the survey, and 85% consented to have their medical records reviewed.

107 compliant study, which included patients who consented to having their medical records used for resea

108 equivocally capable of providing independent consent to higher-risk AD research, providing for an app

109 50 persons at risk for HIV infection who had consented to HIV testing presented at state-funded sites

110 6%) were offered PITC, of whom 1,534 (54.2%) consented to HIV testing.

111 who were HIV uninfected and sexually active consented to HIV-1 RNA testing twice a week and biologic

112 ated within the intensive care unit (n = 93).Consent to ICOD was obtained in 174 cases.

113 y of the interview, the majority of families consented to ICOD.

114 92 individuals (55%) consented to in-depth interview.

115 om repair hospital in all eligible women who consented to inclusion and could provide follow-up data.

116 (aOR 0.68,0.50-0.93 and 0.55,0.28-1.09), and consent to infant blood sample donation (n = 220[48%]) (

117 ipating to help children were more likely to consent to infant blood sample donation.

118 Patients could consent to intensive care or choose care directed at com

119 life decreased, patients were less likely to consent to intensive care.

120 sive care unit admission was associated with consent to intensive care.

121 The patient consented to join a clinical trial for metastatic TCC (U

122 ving cardiac surgery without a history of AF consented to left and right atrial biopsies and a pre-op

123 mpleted self-administered questionnaires and consented to linkage of questionnaire responses with adm

124 l study, 254 men who had been assigned to WW consented to longer-term follow-up.

125 ersons with AD who were thought incapable of consenting to lower-risk or higher-risk studies have pre

126 Current standards of informed consent to neonatal research projects could be improved.

127 parents of 200 babies who had been asked for consent to neonatal trials and 107 neonatologists seekin

128 o lacked a confirmed genetic diagnosis (55%) consented to NGS studies, leading to confirmed diagnoses

129 metropolitan areas provided written informed consent to obtain medical records from all providers who

130 December 6, 2005, and December 9, 2008, 215 consented to ongoing follow-up through at least 7 years

131 querying Siminoff's National Study of Family Consent to Organ Donation database, we find that this si

132 Death was pronounced and the family consented to organ donation.

133 All subjects gave informed consent to participate and were examined using Diagnosti

134 f the follow-on clinical trial gave informed consent to participate in a longitudinal neuroimaging fM

135 vey to patients or surrogates approached for consent to participate in a minimal risk, ICU-based stud

136 for breast cancer, who gave written informed consent to participate in a study evaluating cancer dete

137 Signed consent to participate in an institutional review board-

138 Patients were asked whether they would consent to participate in hypothetical research studies

139 pacity of persons with mental retardation to consent to participate in randomized clinical trials.

140 other neuropsychiatric disorders for giving consent to participate in research has come under increa

141 d cognitive dysfunction can provide informed consent to participate in research is a controversial is

142 fifty-seven individuals were approached for consent to participate in the parent study; none objecte

143 Parents and children gave informed consent to participate in the research.

144 Two patients withdrew their consent to participate in the study, and 5 patients were

145 and were able and willing to provide written consent to participate in the study.

146 s (age range, 52-65 years) provided informed consent to participate in this cross-sectional study.

147 Each subject gave written consent to participate in this HIPAA-compliant, institut

148 Study participants provided written informed consent to participate in this institutional review boar

149 Each subject gave written informed consent to participate in this institutional review boar

150 [standard deviation]) gave written informed consent to participate in this prospective ethics commit

151 Methods Fifteen women gave informed written consent to participate in this prospective HIPAA-complia

152 Subjects provided written consent to participate in this prospective institutional

153 All participants provided informed consent to participate in this study, which was approved

154 All participants provided informed consent to participate in this study, which was approved

155 lmer Ophthalmological Institute, gave verbal consent to participate in this study.

156 undred thirty-two students provided parental consent to participate in this trial.

157 search studies, but the result is that their consent to participate is not fully voluntary.

158 , communal coping is evidenced through joint consent to participate, regular couple counselling and w

159 ofessional were significantly more likely to consent to participate.

160 ere significantly positively associated with consent to participate.

161 cs board, and all patients provided informed consent to participate.

162 evidence of having provided written informed consent to participate.

163 ia, and 634 (9.3%) provided written informed consent to participate.

164 Of 475 vulnerable older patients, 372 (78%) consented to participate and had medical records that co

165 A total of 57 patients consented to participate and were enrolled.

166 Ninety-four patients consented to participate and were randomized (46 to plac

167 n Feb 28, 2000, and Sept 14, 2012, 292 women consented to participate and were randomly assigned to t

168 The 197 individuals that consented to participate in a hospital-based, case-contr

169 Of these, 300 consented to participate in a longitudinal follow-up stu

170 Participants were eligible if they had consented to participate in a phase I cancer study at on

171 f 450, 205 previously sero-negative subjects consented to participate in a second stage of the study

172 Of 1033 eligible RYGB patients who consented to participate in longitudinal research and co

173 If women were not interested in PLCO but consented to participate in our study, they were intervi

174 Of the 1473 eligible residents, 953 consented to participate in the study (mean age, 86 year

175 tioners referred 3170 patients, of whom 2094 consented to participate in the study and were eligible

176 atients had died; 146 of 179 living patients consented to participate in the study.

177 11 case subjects and 553 comparison subjects consented to participate in the study.

178 by second-generation enzyme immunoassay, 122 consented to participate in the study.

179 Ten healthy volunteers consented to participate in the study.

180 A total of 79 individuals consented to participate in the study.

181 ternal biorepository of 123 357 patients who consented to participate in the Total Cancer Care bioban

182 Of 149 eligible patients, 138 consented to participate in the trial and were randomly

183 or metastatic lesions in different locations consented to participate in this institutional review bo

184 he number of individuals (self-selected) who consented to participate was 48968, representing all 50

185 Those who met additional entry criteria and consented to participate were enrolled.

186 undergoing LASIK at the Duke Eye Center who consented to participate were imaged with Placido-ring t

187 Residency directors who consented to participate were informed of pertinent info

188 Those who consented to participate were informed of the nature of

189 All physicians consented to participate with an opt-in or opt-out mecha

190 Of the 285 participants consented to participate, 173 children completed the pro

191 irements for a screening breast US trial and consented to participate, scanned both breasts in all pa

192 ncluding Mohs micrographic surgery), (2) who consented to participate,and (3) who were able to be rea

193 teams contesting during the 2012-2013 season consented to participate.

194 80 +/- 0.6 years; 49% male) undergoing TAVI consented to participate.

195 2004 to March 2005 were informed before they consented to participate.

196 breasts) with numerous known breast lesions consented to participate.

197 s (109 693 individuals) in the control group consented to participate.

198 nd fellows from a training program in Mexico consented to participate.

199 y suspected SH1DF; 170 were eligible and 140 consented to participate.

200 for a mean of 10.8 years (range, 3-24 years) consented to participate.

201 d, responding pathologists were eligible and consented to participate.

202 Twenty-seven of 82 patients consented to participate; 15 and 11 patients were assess

203 Of 6000 veterans telephoned, 1075 consented to participate; 405 of these had chronic pruri

204 t recruitment, 52.8% of eligible individuals consented to participate; retention was 93.2% one year l

205 The authors investigated correlates of consenting to participate in such databases.

206 in hospital for more than 24h and who could consent to participating.

207 Fifty-two patients consented to participating in the study and 22 demonstra

208 h cancer can both understand and voluntarily consent to participation in a clinical trial involving m

209 d (1998 and 1999), a total of 4,894 patients consented to participation in the study.

210 ough a surrogate decision maker-and specific consent to premortem procedures has been given.

211 rst-degree relative signing a donor card, or consenting to procurement of organs after death.

212 Twenty-three patients consented to provide blood DNA samples.

213 Eighty-two percent consented to provide blood, 631 gave permission for DNA

214 s with stage III NSCLC randomized, 360 (85%) consented to QOL evaluation, of whom 313 (88%) completed

215 Of the 49 randomly assigned patients who consented to quality of life assessment (EPP n=23; no EP

216 d in 1,041 of 2,260 registered patients; 716 consented to random assignment (MAP, n = 359; MAP plus I

217 y acceptable; 454 (58% of eligible) patients consented to random assignment between CABG and PCI.

218 factory response to citalopram, patients who consented to random assignment to either cognitive thera

219 4 patients invited to join the trial did not consent to randomisation; 722 were subsequently assigned

220 Difficulty obtaining patient consent to randomization is an important barrier to cond

221 Less than one-third of participants consented to randomization strata that permitted compari

222 th multivessel coronary artery disease; 1829 consented to randomization, and 2010 did not but were fo

223 CS examination outcomes for students who had consented to release of their results.

224 September 2008 to September 2010, 958 women consented to repeat standard breast US supplemented by q

225 and a standardized RCC measure (Capacity to Consent to Research Instrument [CCRI]).

226 The adequacy of subjects' informed consent to research is the focus of an important public

227 ) donor consent forms be expanded to include consent to research on organs and associated retrieved m

228 ctive assessment of children's competence to consent to research participation is currently not possi

229 e capacities of neuropsychiatric patients to consent to research, yet few empirical investigations ha

230 d decision-making capacity and are unable to consent to research.

231 the institutional review board, and patients consented to research authorization.

232 If individuals incapable of consenting to research studies were able to appoint a re

233 f 48 patients with colorectal cancer who had consented to retrospective analysis of hepatic perfusion

234 anced PEComa were treated with sirolimus and consented to retrospective collection of data from their

235 for return and the research participant has consented to return, genomic results, along with referra

236 Consent to review of medical records followed a similar

237 investigation with consent to follow-up and consent to review of medical records were examined.

238 patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and geneti

239 Consent to share data was requested, anonymised for coun

240 Each woman is asked to consent to share information with 1) her obstetric provi

241 e more likely to attend research clinics and consent to skin-prick testing.

242 By contrast, the requirements for consent to storage and specified uses of samples are pre

243 Of the 611 patients consented to study enrollment, 380 met the inclusion cri

244 Of the 611 patients consented to study enrollment, 380 met the inclusion cri

245 sample of adolescent MSM at risk for HIV who consented to study participation.

246 reak patients or their legal representatives consenting to study were enrolled between September 2002

247 Consent to surgery is regulated by the same common law p

248 The patient did not consent to surgical treatment.

249 We propose optimizing informed consent to take into account the psychological, scientif

250 loyees of the chosen organisations who would consent to take part in the study, participants with inf

251 All participants provided informed consent to take part in the trial.

252 Forty-one consecutive patients consented to take part in the study, and twitch pressure

253 students registered in the selected schools consented to take part in the study.

254 d with a patient information sheet and those consenting to take part in the study received standardiz

255 Of 1042 eligible patients, 508 consented to testing.

256 232 (70.7%) of potentially exposed patients consented to testing; 2 were found to have acute infecti

257 Families are often asked to consent to the donation of their deceased relative's org

258 e subjects demonstrated adequate capacity to consent to the hypothetical drug trial, but subjects in

259 tients enrolled for SLN evaluation, 123 gave consent to the OSNA protocol and 156 to the standard his

260 ntify subjects with questionable capacity to consent to the specific research project.

261 al of 89% (3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and

262 Four hundred ninety-eight patients consented to the biomarker analysis: 242 in the XELOX gr

263 he proportion of patients with chlamydia who consented to the online chlamydia pathway who then recei

264 (86%) competed the survey, including 94 who consented to the parent study and 41 who declined.

265 Of the 69 patients who consented to the study, 39 underwent the follow-up fMRI

266 All 34 patients consented to the study, and 29 completed follow-up.

267 1 diabetes and recurrent severe hypoglycemia consented to the study, including standardized meal tole

268 Screening Trial (NLST), and each participant consented to the use of their de-identified images for r

269 All included patients had previously consented to the use of their medical records for resear

270 All patients included had previously consented to the use of their medical records for resear

271 All patients included had previously consented to the use of their medical records for the pu

272 .7% (40 of 106) of those deemed incapable of consenting to the drug RCT and 54.8% (86 of 157) of thos

273 HIV status and ART coverage among adults not consenting to the intervention or HIV testing, although

274 lysis, acceptance of HIV testing among those consenting to the intervention was high, although linkag

275 the 45,399 (77%) men and 55,703 (90%) women consenting to the intervention, 80% of men and 85% of wo

276 Only 7 of 186 (3.8%) were deemed capable of consenting to the neurosurgical RCT by all 5 psychiatris

277 .8% (86 of 157) of those deemed incapable of consenting to the neurosurgical RCT were found capable o

278 e study from archival material from patients consenting to the use of medical records for research pu

279 Male guardians were less likely to consent to their child being tested.

280 None required explicit physician consent to their sharing policies.

281 rity of respondents reported they would have consented to their children being vaccinated if the vacc

282 any institution with access to organ donors consenting to tissue donation for research, and is an in

283 d by the same common law procedures used for consent to treatment.

284 Of 53 eligible surrogates, 32 (60%) consented to treatment allocation.

285 h a life expectancy greater than 4 weeks who consented to treatment with medication.

286 Of the 131 patients who consented to treatment, 29 patients spontaneously resolv

287 When consenting to treatment, few patients adequately underst

288 loan Kettering Cancer Center, 10336 patients consented to tumor DNA sequencing.

289 thods All participants gave written informed consent to undergo brain magnetic resonance imaging and

290 lot study, patients undergoing PCNL provided consent to undergo contrast-enhanced US and fluoroscopic

291 cer who had undergone breast MR imaging gave consent to undergo DE CE digital mammography.

292 prospective donors provide adequate informed consent to undergo the procedure.

293 hirty women undergoing screening mammography consented to undergo a repeated left craniocaudal examin

294 A subset of seven patients also consented to undergo BAL.

295 eligible and evaluable subjects, all of whom consented to undergo both digital and screen-film mammog

296 Of 47 patients approached, 42 consented to undergo detailed neurological evaluations i

297 Of the remaining 162 patients who consented to undergo randomization, 80 were assigned to

298 5 lesions after DCE MR imaging prospectively consented to undergo SWE during second-look US.

299 ed the study and waived the need for patient consent to use all images.

300 Written consent to use examinations was obtained from patients.